3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
9
Phase 2
6
Phase 4
4
Phase 1/2
1
Phase 1
1
Status
Completed
4
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Other hematologic neoplasm
4
Myeloid
3
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
12
Leukemia
4
Leukemia, Myeloid, Chronic-Phase
2
Gastrointestinal Stromal Tumors
2
Blast Crisis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Piebaldism
1
Philadelphia Chromosome
1
Myeloproliferative Disorders
1
Interventions
nilotinib
4
Cytarabine
3
Filgrastim
2
Cyclophosphamide
2
Aprepitant
2
Antilymphocyte Serum
2
rasburicase
1
liposomal amphotericin B
1
fludarabine phosphate
1
fludarabine
1
bosutinib
1
blinatumomab
1
aldesleukin
1
Water
1
Voriconazole
1
Urate Oxidase
1
Tobacco Use Cessation Devices
1
Thiotepa
1
Rituximab
1
Radiotherapy
1
Psychiatric Rehabilitation
1
Prilocaine
1
Polymerase Chain Reaction
1
Pharmacogenomic Testing
1
Pentostatin
1
Palonosetron
1
Oxygen
1
Interleukin-2
1
Inotuzumab Ozogamicin
1
Histamine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Phase 4
×
Leukemia
×
nilotinib
×
Clear all
NCT00980018
2021-07-01
MACS0999
Novartis
Phase 4
Completed
52 enrolled
14 charts
NCT01061177
2017-02-24
'MACS1252
Novartis
Phase 4
Completed
1,090 enrolled
24 charts
NCT00786812
2017-02-23
MACS0439
Novartis
Phase 4
Completed
89 enrolled
NCT01227577
2016-02-08
MACS1428
Novartis
Phase 4
Completed
128 enrolled
11 charts